课题基金 / 基金详情

Identification of pharmacogenomic variants for the prevention of vincristine-induced neurotoxicity.

Identification of pharmacogenomic variants for the prevention of vincristine-induced neurotoxicity.
鉴定药物基因组变异以预防长春新碱引起的神经毒性。
批准号:
274153
负责人:
Ross Colin J
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2012
资助国家:
加拿大
项目状态:
已结题
起止时间:
2012-09-01 至 2013-09-01

项目摘要

项目成果

Ross Colin J的其他基金

相似基金

相关文献

中文摘要
翻译
长春新碱是治疗癌症最有效和最广泛使用的药物之一。然而,长春新碱的临床应用受到削弱和潜在危及生命的药物不良反应(ADR)的显著限制。在孩子
英文摘要
Vincristine is one of the most effective and widely used medications for the treatment of cancer. However, the clinical utility of vincristine is significantly limited by a debilitating and potentially life-threatening adverse drug reaction (ADR). In chil
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
  • 批准号:
    479068
  • 项目类别:
    Operating Grants
  • 资助金额:
    $71.06万
  • 财政年份:
    2023
  • 负责人:
    Ross Colin J
  • 依托单位:
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
  • 批准号:
    477324
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Ross Colin J
  • 依托单位:
Discovery, validation, and pre-clinical development of novel strategies to prevent anthracycline-induced cardiotoxicity.
  • 批准号:
    356014
  • 项目类别:
    Operating Grants
  • 资助金额:
    $41.8万
  • 财政年份:
    2016
  • 负责人:
    Ross Colin J
  • 依托单位:
Pharmacogenetics of Warfarin Safety and Effectiveness in Children.
  • 批准号:
    244057
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.1万
  • 财政年份:
    2011
  • 负责人:
    Ross Colin J
  • 依托单位:
海外基金